The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors

• Hlavní autoři: Xilin Hu (Autor), Hanlin Xu (Autor), Qianwen Xue (Autor), Ruran Wen (Autor), Wenjie Jiao (Autor), Kaihua Tian (Autor)
• Médium: Kniha
• Vydáno: BMC, 2021-10-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

Abstract Background Immune checkpoint inhibitors (ICIs) have witnessed the achievements of convincing clinical benefits that feature the significantly prolonged overall survival (OS) of patients suffering from advanced non-small cell lung cancer (NSCLC), according to reports recently. Sensitivity to...